Open AccessErythropoietin dose and survival of hemodialysis patients
Author(s) -
Mahdi Mohammadian,
Hamid Salehiniya,
Salman Khazaei,
Abdollah Mohammadian-Hafshejani
Publication year - 2017
Publication title -
biomedical research and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 1
ISSN - 2198-4093
DOI - 10.15419/bmrat.v4i7.195
Subject(s) - medicine , hemodialysis , dialysis , peritoneal dialysis , kidney disease , erythropoietin , renal function , kidney , disease , intensive care medicine , stage (stratigraphy) , biology , paleontology
Chronic kidney disease (CKD) is known as a major health problem worldwide (Levey et al., 2007). The CKD is defined as a stage of disease in which the patient's kidney function is less than a half of normal capacity (2). If the kidney function is 10% to 15% less than the normal capacity, the patient has reached the End Stage Renal Disease (ESRD). At this stage, the kidney transplant or dialysis with hemodialysis or peritoneal dialysis is necessary for patient's survival (Levey et al., 2002).